Eurofins Appoints New President for US Microbiology Division
Des Moines, IA, August 2, 2016
Eurofins Scientific announces the appointment of Kally Probasco, President, Eurofins Microbiology Laboratory (EML).
Ms. Probasco will provide dynamic new leadership to Eurofins’ rapidly expanding national network of local food microbiology laboratories.Before her appointment, Ms. Probasco oversaw all US operational functions for the EML group involving successful installations of technical methodologies, strategic account negotiations, key talent acquisition, new lab constructions, and other key initiatives. She was instrumental in the achievement of aggressive growth objectives and quality standards for the division.
She has a Bachelor of Science degree from Iowa State University in Biochemistry and has accumulated vital experience in all aspects of laboratory operations for Eurofins over the years. David Bryant, Senior Vice President of Eurofins North America, Food and Environment Testing said, “We are delighted to have Kally in this important role in our organization as she brings a tremendous amount of energy and strategic leadership to our growing and talented group of food safety testing professionals. In light of the demands that are being placed on food producers, processors, and importers for food safety compliance, we understand how important it is to be a stakeholder in the success of our customers and provide them with cutting edge analytical technologies and unparalleled service to help them meet their challenges with ease and personalized support.”
Today, Eurofins provides a complete array of services in the area of food safety that include comprehensive microbiological testing, a wide array of contaminant detection assays, import detention testing, food safety auditing according to globally recognized and benchmarked industry standards, and an expanding offering of food safety training courses. With recent advancements in microbiomics and innovative logistical solutions, Eurofins continues to enhance its unmatched portfolio of assays and develop new ways to provide customers with greater understanding of their processes and an improved ability to meet their product quality demands in less time.
For more information, visit www.eurofinsus.com/food or email email@example.com.
Notes for the editor:
Eurofins – a global leader in bio-analysis Eurofins Scientific believes it is the world leader in food, environment and pharmaceutical products testing, as well as one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 23,000 staff in more than 225 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 validated analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.